News
4/27/23
The Wall Street Journal: Lisa Khan Blocks Cancer Cures
4/3/23
The Wall Street Journal: The FTC’s Unholy Antitrust Grail
12/13/22
Reuters: Illumina defends $7.1 bln Grail buy to fend off antitrust regulators
11/21/22
Press Release by Senator Tom Cotton: Cotton Expresses Concern Over European Commission Jurisdiction Claim
11/10/22
Law360: Illumina Defends Grail Deal To FTC Commissioners After Win
10/7/22
The Wall Street Journal: Cancer-Detecting Blood Tests Gain Ground as New Market Opens Up
9/11/22
GRAIL: GRAIL Announces Final Results from the PATHFINDER Multi-Cancer Early Detection Screening Study at ESMO Congress 2022
9/7/22
MLex: Illumina-Grail deal not proven by US FTC to be illegal, administrative law judge found
9/6/22
Press Release: Illumina Intends to Appeal European Commission’s Decision in GRAIL Deal
9/1/22
Press Release: Administrative Law Judge Rules in Favor of Illumina in FTC Challenge of GRAIL Deal
7/19/22
MLex: Illumina offers EU concessions over Grail deal as merger-review clock restarts
6/13/22
Barron’s: Illumina Will Be Fine Despite Recent Concerns, Says CEO
3/21/22
POLITICO’s West Wing Playbook: Could Biden’s FTC trip up his cancer moonshot?
1/28/22
New York Times DealBook: Biden Renews Pushback Against Stock Buybacks
1/26/22
MLex: Illumina Will Seek to Overcome EU Antitrust Concerns Over Grail Deal, CEO Says
1/16/22
Financial Times: Illumina Says EU Probe of $8BN Grail Deal Could Hit Biotech Investment
10/8/21
WSJ: Regulatory Hurdles Block a Cancer Miracle
8/18/21
Press Release: Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test
3/30/21
Press Release: Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
9/21/20
Press Release: Illumina to Acquire GRAIL to Launch New Era of Cancer Detection